Screener
Biohaven BHVN R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by Biohaven in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Biohaven’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:07 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001935979-26-000045
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $103,827 | $187,584 |
| General and administrative | 26,601 | 33,977 |
| Total operating expenses | 130,428 | 221,561 |
| Loss from operations | (130,428) | (221,561) |
| Other income, net | 168 | 493 |
| Loss before provision for income taxes | (130,260) | (221,068) |
| Provision for income taxes | 272 | 609 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Biohaven's R&D?
- Biohaven (BHVN) reported R&D of $103.83M in Q1 2026.
- How has Biohaven's R&D changed year-over-year?
- Biohaven's R&D decreased by 44.7% year-over-year, from $187.58M to $103.83M.
- What is the long-term trend for Biohaven's R&D?
- Over 3 years (2022 to 2025), Biohaven's R&D has grown at a 13.3% compound annual growth rate (CAGR), from $437.07M to $635.07M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Biohaven's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude